GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Combined entity is better positioned to compete in increasingly competitive generics industry
This tie-up will have no impact on any other brands of the company
_256_384.jpg)
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
The Issue opened on June 18, 2024 and closed on June 21, 2024
Renews GMP certifications for India and Malaysia sites
The company will now explore a buyer for its manufacturing site and exit in due course
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Subscribe To Our Newsletter & Stay Updated
